CTNM - Contineum Therapeutics, Inc. Class A Common Stock

https://www.contineum-tx.com

Momentum: Bearish

Recent News

No recent news found.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company is headquartered in San Diego, California.

52W High

$20.30

52W Low

$3.35

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

20.76

EV/Revenue (<3 favorable)

8.25

P/S (TTM) (<3 favorable)

11.15

P/B (<3 favorable)

1.88

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

1.61%

Institutions (25–75% balanced)

73.94%

Shares Outstanding

21,625,200

Float

14,969,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

Gross Profit (TTM)

EPS (TTM)

-2.07

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

N/A

ROE (TTM) (>15% strong)

-0.29%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

N/A

Momentum

Bearish momentum

Value

1.6191

1.6248

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025